StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.13−0.24 (-3.26%)

Close on Nov 17, 2026Market cap $382.38MP/E –Yield –

Earnings

Avalo Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 22, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.34
-$2.19 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Avalo Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 22, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open––-$0.34Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open––-$0.83Release
Q1 FY2026ended Mar 31, 2026May 13, 2026before the open––-$0.98Release
Q4 FY2025ended Dec 31, 2025Mar 23, 2026before the open–––Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open––-$2.19Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open––-$1.92Release
Q1 FY2025ended Mar 31, 2025May 12, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Mar 20, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$249.00K+5.5%-$2.83Release
Q2 FY2024ended Jun 30, 2024Aug 12, 2024before the open––-$14.07Release
Q1 FY2024ended Mar 31, 2024May 13, 2024before the open––-$141.00Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Avalo Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Avalo Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Avalo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. News
  5. Results
  6. News
  7. News
  8. Update
  9. Results
  10. Results
  11. News
  12. Results
  13. News
  14. News
  15. News

See a number that looks wrong?